15 results
8-K
EX-99.2
BOLT
Bolt Biotherapeutics Inc
29 Mar 23
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:13pm
, there remains an urgent need for innovation,” said Bob T. Li, M.D., Ph.D., MPH, medical oncologist, and principal investigator at Memorial Sloan
DEF 14A
BOLT
Bolt Biotherapeutics Inc
28 Apr 22
Definitive proxy
4:06pm
and ensuring we listen to our employees.
We value innovation, passion, data-driven decision making, persistence and honesty. We are building an environment
8-K
EX-99.1
ex22cwqrcu5oaja 04j
2 Jun 21
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
8:01am
10-K
b2obd 9ungg3tod
31 Mar 21
Annual report
4:06pm
424B4
m6kobdsj
5 Feb 21
Prospectus supplement with pricing info
4:44pm
S-1/A
z2r41p
1 Feb 21
IPO registration (amended)
6:24am
S-1
b5oierkbt 3uz
15 Jan 21
IPO registration
3:58pm
DRS/A
zvismknhfri5y9hq5
11 Jan 21
Draft registration statement (amended)
12:00am
DRS/A
zsixjye
11 Sep 20
Draft registration statement (amended)
12:00am
DRS
xxzbxcrla2iuv0n0
10 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next